United Therapeutics Corporation or Grifols, S.A.: Who Invests More in Innovation?

Who Leads in R&D: United Therapeutics vs. Grifols?

__timestampGrifols, S.A.United Therapeutics Corporation
Wednesday, January 1, 2014180753000242549000
Thursday, January 1, 2015224193000245098000
Friday, January 1, 2016197617000147600000
Sunday, January 1, 2017288320000264600000
Monday, January 1, 2018240661000357900000
Tuesday, January 1, 20192760180001182600000
Wednesday, January 1, 2020294216000357700000
Friday, January 1, 2021354881000540100000
Saturday, January 1, 2022361140000322900000
Sunday, January 1, 2023330551000408000000
Loading chart...

Igniting the spark of knowledge

Innovation Investment: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, innovation is key. United Therapeutics Corporation and Grifols, S.A. have been at the forefront of this race, investing heavily in research and development (R&D) over the past decade. From 2014 to 2023, United Therapeutics consistently outpaced Grifols, with an average R&D expenditure of approximately 48% more. Notably, in 2019, United Therapeutics' R&D spending peaked, reaching nearly four times its 2016 investment. Meanwhile, Grifols showed a steady increase, culminating in a 100% rise from 2014 to 2022. This trend underscores the strategic importance both companies place on innovation, yet highlights United Therapeutics' more aggressive approach. As the industry evolves, these investments will likely play a pivotal role in shaping the future of healthcare solutions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025